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 ABSTRACT
 Current invasive procedures [amniocentesis 
and chorionic villus sampling (CVS)] pose a risk 
to mother and fetus and such diagnostic procedures 
are available only to high risk pregnancies limit-
ing aneuploidy detection rate. This review seeks to 
highlight the necessity of investing in non invasive 
prenatal diagnosis (NIPD) and how NIPD would 
improve patient safety and detection rate as well as 
allowing detection earlier in pregnancy.
 Non invasive prenatal diagnosis can take either 
a proteomics approach or nucleic acid-based ap-
proach; this review focuses on the latter. Since the 
discovery of cell free fetal DNA (cffDNA) and fe-
tal RNA in maternal plasma, procedures have been 
developed for detection for monogenic traits and 
for some have become well established (e.g., RHD 
blood group status). However, NIPD of aneuploi-
dies remains technically challenging. This review 
examines currently published literature evaluating 
techniques and approaches that have been suggested 
and developed for aneuploidy detection, highlight-
ing their advantages and limitations and areas for 
further research.
 Keywords: Aneuploidy; Cell free fetal DNA 
(cff DNA); Non invasive prenatal diagnosis (NIPD).
 
INTRODUCTION
 Current invasive diagnostic techniques pose 
a risk to mother and fetus. The National Health 
Service (NHS) offers prenatal screening to all preg-
nant women in England [1]. At 11 to 13 weeks ges-
tation a combination of tests (termed the combined 
test) are performed to screen for abnormalities and 
score the risk of the fetus having Down’s syndrome 
(trisomy 21) (T21). The combined test includes ul-
trasound scans to check nuchal translucency and 
analyzing maternal blood samples for free b human 
chorionic gonadotrophin and pregnancy-associated 
plasma protein A concentrations. These are com-
bined with factors such as maternal age, pregnancy 
histories and familial genetic conditions [1]. Women 
with high risk pregnancies are then offered prenatal 
diagnosis. Current diagnostic procedures take sam-
ples for karyotyping through invasive means, pos-
ing a risk to mother and fetus.
 Chorionic villus sampling (CVS) can be per-
formed from 10 weeks; taking a tissue sample 
from the placenta through the cervix or abdomen. 
Amniocentesis can be performed from 15 weeks by 
obtaining a sample of amniotic fluid by passing a 
needle through the mother’s abdomen into the uter-
us [1]. The rate of miscarriage associated with CVS 
and amniocentesis is 1.0 to 2.0%. Despite the risks, 
on average 5.0-10.0% of pregnant women chose to 
undergo these tests [2], averaging approximately 
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23,700 invasive diagnostic tests per year [1]. The 
combined test has a 5.0-9.0% false positive rate 
[3,4]; consequently mothers with healthy fetuses 
may choose to undergo unnecessary invasive diag-
nostic procedures, putting the fetus at risk of iatro-
genic spontaneous abortion. Non invasive prenatal 
diagnosis (NIPD) would pose no such risk.
 Increasing maternal age increases risk of Down’s 
syndrome, Edwards’ syndrome (trisomy 18) (T18) 
and Patau’s syndrome (trisomy 13) (T13), the three 
most common autosomal aneuploidies in live births. 
In the early 1970s, about 5.0% of pregnant women 
were 35 years or over. However, almost 20.0% are 
now over 35, increasing the incidence of aneuploid 
fetuses [5]. Trisomy 18 and T13 are currently not 
screened for until fetal anomaly ultrasound screen-
ing at 18 to 20+6 weeks [1]. However, the NHS state 
that although abortion is legal up to 24 weeks, it 
should be carried out as early as possible, ideally 
before 12 weeks [6]. Therefore, preferably, detec-
tion of all aneuploidies would be made within the 
first trimester, which would give greater scope for 
parental choice. It is hoped that NIPD could help 
achieve this.
 Despite increasing maternal age, approximately 
80.0% of Down’s syndrome patients are stillborn 
to those under 35 [7]. Currently diagnostic tests 
are only offered to those with high risk pregnancies 
(such as those with abnormal serum protein levels) 
as the risk of having a fetus with an abnormality 
must be balanced against the risk of miscarriage. 
This inevitably results in some abnormalities being 
missed as women under 35 years are not considered 
at risk of having a Down’s syndrome fetus [7]. Non 
invasive prenatal diagnosis would allow testing 
of these low-risk pregnancies. A recent European 
Commission (EC) funded project, SAFE (Special 
non-invasive advances in fetal and neonatal evalu-
ation) explored a number of new technologies in 
NIPD [8,9], and this has been extended in a recent 
project funded by the UK National Institute for 
Health Research (NIHR), RAPID, and a EC frame-
work 7 program, Eurogentest 2.
 In summary, prenatal testing is important as 
it allows possible health issues of the baby to be 
identified before birth, allowing arrangements for 
immediate care to be made. It also enables parents 
to make an informed choice regarding whether to 
terminate the pregnancy. Replacing current invasive 
tests with NIPD would reduce risk and increase de-
tection rate.
 Methods for Non Invasive Prenatal Diagnosis 
of Aneuploidies. The importance of prenatal diag-
nosis and risk posed by invasive techniques makes 
NIPD research a worthwhile commitment morally 
and commercially. Research originally focused on 
fetal nucleated cells found in maternal circulation 
[10-12]. A number of cell types were investigated 
but subsequently ruled out for a variety of reasons. 
These include lack of fetal specific markers [13], 
entrapment in the maternal lungs, confined placen-
tal mosaicism [14] and persistence in the maternal 
circulation years after pregnancy [15]. Furthermore, 
only one or two fetal nucleated cells are found per 
mL of maternal blood, further hampering their use 
[7]. Research now focuses on cell free fetal DNA 
(cffDNA), which was discovered in maternal plas-
ma in 1997 [10]. It has since been reported to be 
present from as early as 4 weeks gestation [16], 
making it possible for NIPD to be achievable ear-
lier in pregnancy than invasive methods. It has a 
short circulation half-life (»16 min.) and is unde-
tectable in the maternal circulation within 2 hours 
postpartum [17], making it specific to the current 
pregnancy. Technical challenges stem from the fact 
cffDNA constitutes only 3.0 to 6.0% of cell free 
DNA in maternal plasma [7,10]. Detection of pater-
nally inherited alleles in maternal plasma is quali-
tative; however, direct detection of aneuploidies is 
reliant on dose, therefore quantitative. Therefore, it 
was originally assumed that direct measurement of 
fetal chromosome dose in maternal plasma would 
show maternal chromosome dose and fetal chro-
mosome dose would be lost in the background of 
maternal DNA. Nevertheless, chromosome dose 
methods have been developed and are discussed 
later. Methods for aneuploidy detection originally 
focused on fetal markers for allelic ratio analysis.
 Non Invasive Prenatal Diagnosis in Routine 
Clinical Practice 2012. Following the discovery 
of cffDNA in maternal plasma in 1997 [10], testing 
for fetal RHD blood group status rapidly evolved 
from risky DNA testing of amniotic fluid samples 
provided from Liley curve investigations [18] to the 
world’s first routine application of a non invasive 
prenatal test clinically [19]. Fetal blood grouping 
using maternal plasma as a source of fetal DNA is 
now used extensively worldwide [20]. In addition, 
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the detection of other paternally inherited alleles or 
chromosome is possible, for example, fetal sexing 
(for review, see [21]). Most clinically applicable 
methods utilize the simple real time polymerase 
chain reaction (ReTi-PCR) approach, however, 
methods to detect the most commonly requested 
prenatal diagnostic test, for aneuploidy, require 
more sophisticated approaches. This is primarily 
due to the fact that maternal DNA is an admix of fe-
tal (derived from the placenta) and maternal DNA.
 METHODS TO DETECT FETAL 
ANEUPLOIDY BY NON INVASIVE 
PRENATAL DIAGNOSIS
 Methods Based on Allelic Ratio: RNA-Single 
Nucleotide Polymorphism Allelic Ratio Approach. 
The presence of free fetal RNA (ffRNA) in maternal 
plasma was established in 2000 by Poon et al. [22] 
who showed that Y chromosome-specific zinc fin-
ger protein (ZFY) mRNA could be found in the plas-
ma of women carrying a male fetus. Further studies 
showed that ffRNA is surprisingly stable [23] and 
present in maternal plasma as early as 4 weeks ges-
tation [24]. As different tissues express their own 
individual mRNA profiles, it follows that some 
mRNAs may be placenta-specific and therefore fe-
tal specific. Ng et al. [25] showed that placenta spe-
cific mRNAs could be detected in maternal plasma, 
and in 2007, a placental-specific mRNA transcribed 
from PLAC4 on chromosome 21 was discovered 
[26]; use of these could circumvent the problems 
caused by maternal background DNA.
 Lo et al. [26] developed the RNA-SNP (single 
nucleotide polymorphism) allelic ratio approach. 
This technique exploits SNPs that cause sequence 
variation between alleles. A heterozygous euploid 
fetus should yield equal proportions of each allele, 
giving an allelic ratio of 1:1. However, a heterozy-
gous triploid fetus would yield the allelic ratio 1:2 
or 2:1 [27]. Lo et al. [26] used reverse transcription 
(RT)-PCR to amplify a PLAC4 SNP containing lo-
cus, followed by primer extension. Mass spectrom-
etry was then used to determine allelic ratio (Figure 
1). Maternal plasma of 57 women carrying euploid 
fetuses and 10 carrying T21 fetuses was analyzed. 
The method had a sensitivity of 90.0% and specific-
ity of 96.0% [26]. Larger trials to refine the normal 
reference ranges could potentially improve sensitivi-
ty and specificity [27]. Regrettably, RNA-SNP allelic 
ratio methods are limited to fetuses heterozygous for 
the SNP under analysis. Among 119 placentas geno-
typed by Lo et al. [26] for the most common PLAC4 
SNP (rs8130833), 42.0% were homozygous and the 
method would have therefore been uninformative.
Figure 1. Schematic representation of Digital PCR.
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 The Digital RNA-Single Nucleotide 
Polymorphism Allelic Ratio Approach. The digi-
tal RNA-SNP allelic ratio approach is an adaptation 
to the RNA-SNP allelic ratio method made to utilize 
the sensitivity of digital PCR [28]. Rather than one 
reaction mix, digital PCR involves thousands of re-
actions running in parallel. The template strand so-
lution is diluted so that a maximum of one template 
strand is added to each reaction. Lo et al. [28] used 
384-well plates for digital ReTi-PCR of the PLAC4 
SNP, rs8130833. Uninformative wells (i.e., those 
containing no or multiple signals) were discounted 
and wells containing A or G PLAC4 allele were 
counted and their ratio calculated. Using maternal 
plasma RNA samples, four T21 fetuses and nine eu-
ploid were correctly identified. However, although 
digital PCR is more sensitive than ReTi-PCR, the 
digital RNA-SNP allelic ratio approach it is still 
limited to heterozygous fetuses. The methodology 
entered commercial trials under the governance of 
Sequenome Inc. (San Francisco, CA, USA) but was 
subsequently found to be an unreliable technology 
and unlikely to see routine application in NIPD.
 Epigenetic Allelic Ratio Approach. The epi-
genetic allelic ratio (EAR) approach is similar to 
the RNA-SNP allelic ratio approach but rather than 
targeting fetal specific mRNA, it exploits epigen-
etic phenomena that alter DNA expression without 
altering sequence; the most well known of these is 
cytosine methylation. Methylation patterns differ 
between tissues; genes that are differentially meth-
ylated between mother and fetus have been iden-
tified allowing an opportunity to selectively target 
fetal-specific DNA with the use of methylation spe-
cific primers [22,27].
 Chim et al. [29] demonstrated that the maspin 
gene (SERPINB5) promoter is unmethylated 
(U-mapsin) in the placenta but hypermethylated 
in maternal blood cells. SERPINB5 is located at 
18q21.33 [30], providing the opportunity for an 
EAR-based approach to T18 detection. Tong et al. 
[30] used the EAR approach, first using bisulphite 
conversion followed by methylation-specific PCR 
and primer extension reactions designed to distin-
guish the A and C allele of U-mapsin based on size 
[30]. The test had a sensitivity of 100.0% but had a 
9.7% false positive rate [30]. Theoretical modelling 
suggested that 200 sequence copies were needed at 
the start of PCR to achieve diagnostic sensitivity and 
specificity of 97.0%. However, bisulphite conver-
sion has been reported to cause DNA degradation 
of up to 96.0% [30]. Taking this into account, Tong 
et al. [30] predicted that only 20 sequence copies 
would have remained in their samples after bisul-
phite conversion due to low blood volume used; this 
could explain the high false positive rate.
 Although the EAR approach was successfully 
demonstrated, strategies need to be developed to 
overcome DNA degradation by bisulphite conver-
sion. Weber et al. [31] described a way of enriching 
methylated DNA using immunoprecipitation with 
the use of an antibody against 5-methylcytosine; 
methylated DNA immunoprecipitation (MeDiP) 
has since been used to successfully enrich fetal hy-
permethylated DNA [32]. Alternatively, degrada-
tion of maternal unmethylated DNA by bisulphite 
conversion would be acceptable so targeting genes 
hypermethylated in the placenta but hypomethyl-
ated in maternal tissues could be a solution [3].
 Despite various groups showing methods based 
on allelic ratio to work successfully, all are limited 
to heterozygous fetuses. However, an allelic ratio 
method could still have potential for use in practice 
if multiple SNPs, with a combined heterozygosity 
rate high enough to cover the general population, 
were analyzed [27]. Allelic ratio methods also as-
sume both alleles are transcribed at an equal rate, 
which is not always true [4], meaning analysis of 
transcript ratios could be unreliable. However, suc-
cessful demonstration of allelic ratio methods sug-
gests this is not problematic. Finally, although al-
lelic ratios may successfully identify trisomies they 
would not detect monosomies.
 Methods Based on Relative Chromosome 
Dosage. Using microfluidics digital PCR, Lun et al. 
[33] re-evaluated the percentage of cell free DNA 
that was fetal in maternal plasma and found there 
was a median 9.7% in the first trimester rising to 
20.4% by the third trimester. These levels are higher 
than previously thought, suggesting direct measure-
ment of fetal chromosome dose may be possible 
without prior enrichment. Relative chromosome 
dose approaches work on the principal that in a 
normal fetus the ratio of two chromosomes should 
be 2:2. Comparing an affected chromosome in a 
triploid fetus would give the ratio 3:2. A number 
of methods based on chromosome dose have been 
reported and are described below.
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 Epigenetic-Genetic and Epigenetic-Epigenetic 
Chromosome Dosage Approaches. Tong et al. [34] 
combined a methylation restricted digest to digest 
hypomethylated DNA and microfluidics digital PCR 
to measure HLCS on chromosome 21 (a hypermeth-
ylated fetal marker), RASSF1A on chromosome 3 
(a hypermethylated fetal marker) and ZFY on the 
Y chromosome. The epigenetic-epigenetic chromo-
some dosage approach comparing hypermethyl-
ated HLCS and RASSF1A ratio showed too great an 
overlap between euploid and T21 fetuses. However 
the epigenetic-genetic chromosome dosage ap-
proach comparing hypermethylated HLCS and ZFY 
ratio in euploid and T21 fetuses was discriminative 
but limited to male fetuses. Other groups have also 
successfully used the EGG chromosome dose ap-
proach, for example, Tsui et al. [35] identified T18 
fetuses with a sensitivity of 88.9% and specificity 
of 96.3%. However, Tsui et al. [35] also used ZFY 
limiting use to male fetuses. ZFY is often used for 
proof of principal studies but epigenetic-genetic 
(EGG) chromosome dosage needs to be success-
fully demonstrated with sex-independent markers 
before it can be used in practice.
 Digital Relative Chromosome Dosage Method. 
There is a 1.5-fold increase in relative chromosome 
dose in trisomies. Due to the exponential increase 
in template strand number in ReTi-PCR, it is not 
suited to detecting differences in template strand 
concentrations below 2-fold [4,36,37]. Digital PCR 
provides a more accurate measure of template strand 
concentration.
 Methodology involves the amplification of mul-
tiple targets on different chromosomes in many thou-
sands of different PCR reactions (microfluidic PCR 
or droplet PCR). In this example, two regions of the 
human genome have been amplified, chromosomes 
18 and 21. The relative abundance of the target DNA 
is defined directly against one another, and thus a sta-
tistical 1:1 ratio of each chromosome would indicate 
a euploid fetus and a (theoretical) 2:1 ratio (21:18) 
would indicate aneuploidy. Despite the admix of fetal 
and maternal DNA in maternal plasma, like next gen-
eration sequencing (NGS) (see Figure 2), digital PCR 
is able to differentiate such a difference, although 
clearly the actual difference in ratio would not be 2:1 
due to the presence of maternal DNA.
 The digital relative chromosome dosage (RCD) 
method directly targets a non polymorphic locus on 
the chromosome of interest and on a reference chro-
mosome without differentiating between maternal 
and fetal DNA. Lo et al. [28] used digital PCR to 
measure a non polymorphic locus on chromosome 
21 and chromosome 1. The number of wells in 
which there was a positive PCR for either locus was 
counted and their relative dose calculated. Euploid 
and T21 fetuses in artificial mixtures of placental 
and maternal DNA were successfully identified but 
the method was not tested using maternal plasma 
from T21 pregnancies. However, despite RCD not 
differentiating between maternal and fetal DNA, 
computer modeling estimated 97.0% of fetuses 
would be correctly identified by 7680 digital PCRs 
in cases where the cffDNA constituted 25.0% of the 
DNA [28]. Nevertheless, this is higher than previ-
ously reported levels in maternal plasma. Moreover, 
other groups have shown the digital RCD approach 
to be feasible with fetal fractions of 10.0% [38] al-
though some level of enrichment may still first be 
needed for use in the first trimester.
 Next Generation Sequencing (NGS) or 
Massively Parallel Sequencing. Massively paral-
lel sequencing (MPS) is a method through which 
the entire genome can be sequenced using millions 
of short sequence reads. These are then reassembled 
by a computer program using genomic databases to 
compare the reads to the known genomic sequence 
[3,4,39]. A number of groups have demonstrated 
Figure 2. Schematic representation of next-generation se-
quencing based approaches for NIPD of fetal aneuploidy. The 
figure represents the numbers of targets from each chromosome 
(X-axis) identified by NGS as colored dots. Based on statistical 
counting of each chromosome (Z-score), a higher proportion 
of chromosome 21 signals can be shown in maternal plasma 
samples despite this being an admix of maternal and fetal DNA. 
The approach can include whole genome sequencing, or target-
ed sequencing of various chromosomes following amplification
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that if cffDNA is sequenced in this way and the se-
quence reads assigned to each chromosome are then 
counted, whether a chromosome is over- or under-
represented can then be calculated [39,40]. This is 
similar to the approach taken for the digital relative 
chromosome dose method. However, NGS gener-
ates far more sequence reads, possibly over 60,000 
for chromosome 21 alone, suggesting it should be 
more sensitive to small changes in genomic rep-
resentation [4]. The NGS could therefore have the 
potential of identifying partial trisomies, although 
further research is needed to investigate this.
 Fan et al. [39] were able to identify nine T21 cas-
es, two T18 and one T13, distinguishing them from 
six normal euploid cases, using shot gun sequencing 
(Figure 2). However, the blood samples used in this 
study were drawn 15 to 30 min. following an inva-
sive procedure, this may have influenced the results 
by introducing additional fetal DNA into the mater-
nal circulation [3]. Furthermore, Fan et al. [39] argue 
that using a digital PCR assay, they estimated fetal 
DNA in their samples constituted <10.0% of total 
cell free DNA, in line with previous studies.
 More recent studies have taken into account 
that differing GC contents between chromosomes 
results in nonuniform sequencing by MPS and cor-
rected genomic representation to account for CG 
content. By doing this, Chen et al. [40] found that 
a specificity and sensitivity of 98.9 and 100.0%, re-
spectively, could be achieved for T13 detection and 
98.0 and 91.9%, respectively for T18 detection.
 In light of recently successful studies, Ehrich et 
al. [41] conducted a blinded study on 449 plasma 
samples from pregnant women (39 with T21 fetus-
es), using the most up-to-date sequencing technolo-
gy available at the time, to investigate NGS for T21 
diagnosis. Z-scores described in [42] were used to 
standardize genomic representation and classify the 
fetus as euploid or T21. The results were very suc-
cessful with a sensitivity of 100.0% and specificity 
of 99.7%, suggesting that if the cost of MPS could 
be reduced it could be used in practice. Recently, 
using the single molecule sequencing technology 
of Helicos (Cambridge, MA, USA) that does not 
require a prior DNA amplification step, van den 
Oever et al. [43] have demonstrated a greater sen-
sitivity of this platform above that of Illumina GA-
II (San Diego, CA, USA) used in previous studies. 
This may lead to utilization of NGS much earlier in 
NIPD, perhaps within the first trimester [44], as the 
study demonstrated detection of trisomy 21.
 All three relative chromosome dose methods 
discussed are polymorphism-independent and have 
successfully demonstrated the ability to detect triso-
mies. Of the three relative chromosome dose meth-
ods, NGS seems the most promising as, due to the 
large amount of data it produces, it has high sen-
sitivity and specificity. It can also simultaneously 
provide information on chromosome dose for all 
chromosomes, and theoretically, has the potential to 
detect partial trisomies and monosomies, although 
this needs to be validated by further research.
 Methods to Enrich Fetal DNA. One of the main 
hindrances on NIPD is the dilution of fetal DNA in 
maternal blood; this makes the quantitative nature of 
aneuploidy diagnosis difficult. Therefore, a number 
of methods have been investigated to enrich or pre-
vent the dilution of fetal DNA in maternal plasma.
 Use of Formaldehyde. In 2004, Dhallan et 
al. [45] hypothesized that a significant portion of 
maternal DNA in maternal plasma is leaked from 
maternal leukocytes following venipuncture due to 
physical forces put on them during collection and 
subsequent handling. Blood was collected from 69 
pregnant women in tubes containing a 4.0% form-
aldehyde neutralizing buffer. Analysis showed the 
majority of samples had >25.0% fetal DNA and 
27.5% had >50.0%, suggesting formaldehyde treat-
ment could successfully prevented leukocyte rup-
ture. However, no untreated blood was collected 
in this trial so no comparisons between treated and 
untreated samples could be made. Since 2004, a 
number of groups have attempted to replicate the 
enrichment of fetal DNA in maternal plasma using 
formaldehyde without success [46,47].
 Separation Based on Size by Gel Electro-
phoresis. Another approach to fetal enrichment is 
to separate cffDNA from maternal based on size. 
This can be done by gel electrophoresis [48]. In ear-
ly pregnancy (13 + 2 weeks gestational ages), Li et 
al. [48] found that 85.5% of fetal DNA is less than 
0.3 kb. Fetal DNA also constituted 28.4% of the 
<0.3 kb fraction in maternal plasma, increasing to 
68.7% in the third trimester. A study by Chan et al. 
[49] supports Li et al. [48], concluding that >99.0% 
of fetal derived DNA is shorter than 313 bp. Gel 
electrophoresis has since been used to successfully 
enrich fetal DNA for detection of point mutation in 
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b-thalassemia [50]. However, isolation of size frac-
tions by gel electrophoresis is considered too time 
consuming and prone to contamination to allow its 
widespread use [3].
 Co-Amplification at Lower Denaturation 
Temperature Polymerase Chain Reaction. In 
2008, Li et al. [51] reported on (co-amplification 
at lower denaturation temperature) COLD-PCR, a 
variation of PCR that can selectively amplify mi-
nority alleles from a background of wild-type al-
leles. This technique works on the basis that even 
a single nucleotide difference between the minor-
ity and wild-type allele may lower the critical de-
naturation temperature (Tc). If so, the minority al-
lele could be denatured at a lower temperature than 
the wild-type sequence, allowing only the minor-
ity allele sequence to bind with the primers and be 
amplified [52]. Li et al. [51] used COLD-PCR to 
identify mutations in a number of genes associated 
with human cancer that had previously been missed 
and suggested that COLD-PCR could also be used 
for detection of “fetal alleles in maternal blood.” 
However, in aneuploidies there may be no sequence 
difference between the maternal and fetal allele of 
interest. Moreover, it is possible that the shorter 
length of cffDNA in comparison with maternal cell 
free DNA may allow COLD-PCR to denature cffD-
NA at a temperature at which maternal DNA would 
remain double-stranded, allowing only cffDNA to 
be amplified. There is currently no published study 
on the enrichment of fetal DNA from maternal plas-
ma using this method but this could be a promising 
technique. If fetal DNA could be enriched in this 
way, not only could it aid detection of aneuploidies 
but also aid detection of monogenic diseases where 
a disease allele may have been maternally inherited.
 Proteomics for New Down’s Syndrome Bio-
markers (for review, see [53,54]). Despite the 
advances in molecular counting technologies, espe-
cially NGS and digital PCR, better serum screening 
biomarkers for Down’s syndrome and other condi-
tions are still an option, as NGS and digital PCR 
methodologies are not yet applicable to mass-scale 
screening. For this reason several large scale studies 
were launched to analyze the maternal plasma pro-
teome in pregnancies where the mother was carrying 
a Down’s syndrome fetus [53,55-60]. It is clear that a 
number of overlapping biomarkers have been identi-
fied, but the search for a truly differentiating trisomy 
21 biomarker using this approach may still be a way 
off, but may well be worth the effort expended.
 CONCLUSIONS
 In summary, despite various non invasive 
methods invented to diagnose aneuploidy, none 
are yet used in practice. Methods described in the 
current literature can be split into methods based 
on allelic ratio or chromosome dose. Allelic ratio 
methods are held back by their restriction to hetero-
zygous fetuses, yet if a combination of SNPs could 
be used, their combined heterozygosity rate could 
potentially cover the general population. However, 
allelic ratio approaches would still be unable to 
diagnose monosomies. Chromosome dose meth-
ods have the advantage of being polymorphism-
independent and have the potential to diagnose 
trisomies, monosomies and in the case of NGS-
based methods, possibly even partial trisomies but 
this needs to be verified by further research. For 
these methods to be introduced into practice, fur-
ther research needs to be aimed at simplifying the 
methods and reducing the cost. Another approach 
would be to selectively enrich cffDNA or deplete 
maternally derived cell free DNA to overcome the 
problem of low cffDNA concentration in maternal 
plasma; this would allow more straight-forward 
analysis methods to be used. Co-amplification at 
lower denaturation temperature-PCR seems the 
most promising enrichment technique discussed 
but requires further investigation.
 With the progress made in NIPD since the dis-
covery of cffDNA, and invention of new sequenc-
ing techniques, it is not over optimistic to predict 
that NIPD will be used in practice in the near future; 
improving detection rate, allowing earlier diagnosis 
and eliminating iatrogenic fetal loss and risk to the 
mother due to invasive procedures.
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